纤维酸使用与过敏性心肌病的临床表现的关联
Chan Soon Park1, Bongseong Kim2, Jin-Hyung Jung2
1Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea.
ESC heart failure
|July 26, 2024
概括
纤维酸使用与降低过度缩性心肌病 (HCM) 表现的风险有关. 这种保护作用在肥胖,代谢问题和不健康的生活方式习惯的人中更为明显.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖和代谢异常与高性心肌病 (HCM) 的临床表现有关.
- 降脂剂,特别是纤维素对HCM表现的影响需要进一步调查.
研究的目的:
- 调查纤维酸使用与高伤性心肌病 (HCM) 的临床表现之间的关联.
- 为了确定使用纤维化物治疗脱脂症是否会影响HCM的发展或进展.
主要方法:
- 一个全国性的数据库被用来选2010年至2017年期间用纤维酸治疗的患者.
- 建立了一个1:1匹配的纤维素素素素的参与者队列,不包括以前有HCM诊断的患者.
- 在1年的滞后阶段之后,在5年的时间内确定了HCM事件事件.
主要成果:
- 纤维素的使用与临床HCM表达的风险明显降低 (HR:0.763;95%CI:0.630-0.924).
- 在患有肥胖 (BMI ≥25 kg/m2,腹部肥胖),高甘油三 (≥150 mg/dL) 和代谢综合征的患者中,保护性关联更为突出.
- 纤维在当前吸烟者,酒精消费者和身体活动水平较低的人群中显示出更大的预后益处.
结论:
- 纤维化疗法与临床多变性心肌病变的发病率降低有关.
- 纤维酸对HCM风险的有益影响在患有肥胖,失脂症,代谢综合征和不良生活方式因素的个体中更为明显.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
414
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
414
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
813
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
813
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
155
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
155
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
614
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
614
Heart Failure Drugs: β-Blockers
333
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
333


